![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Departments of Neurology (R.E.B., S.S., D.C.L., B.D.M., R.J.D.), Pharmacology and Toxicology (R.J.D.), and Molecular Biophysics and Biochemistry (R.J.D.), Virginia Commonwealth University, Richmond, Virginia
Altered GABAergic inhibitory tone has been observed in association with a number of both acute and chronic models of epilepsy and is believed to be the result, in part, of a decrease in function of the postsynaptic GABAA receptor (GABAAR). This study was carried out to investigate if alterations in receptor internalization contribute to the decrease in GABAAR function observed with epilepsy, utilizing the hippocampal neuronal culture model of low-Mg2+-induced spontaneous recurrent epileptiform discharges (SREDs). Analysis of GABAAR function in "epileptic" cultures showed a 62% reduction in [3H]flunitrazepam binding to the GABAA
receptor subunit and a 50% decrease in GABA currents when compared with controls. Confocal microscopy analysis of immunohistochemical staining of GABAAR
2/
3 subunit expression revealed approximately a 30% decrease of membrane staining in hippocampal cultures displaying SREDs immediately after low-Mg2+ treatment and in the chronic epileptic state. Low-Mg2+-treated cultures internalized antibody labeled GABAA receptor with an increase in rate of 68% from control. Inhibition of GABAAR endocytosis in epileptic cultures resulted in both a recovery to control levels of membrane GABAA
2/
3 immunostaining and a total blockade of SREDs. These results indicate that altered GABAAR endocytosis contributes to the decrease in GABAAR expression and function observed in this in vitro model of epilepsy and plays a role in causing and maintaining SREDs. Understanding the mechanisms underlying altered GABAA R recycling may offer new insights into the pathophysiology of epilepsy and provide novel therapeutic strategies to treat this major neurological condition.
Address correspondence to: Dr. Robert J. DeLorenzo, Virginia Commonwealth University, School of Medicine, P.O. Box 980599, Richmond, VA 23298. E-mail: rdeloren{at}hsc.vcu.edu
This article has been cited by other articles:
![]() |
J. O. McNamara, Y. Z. Huang, and A. S. Leonard Molecular Signaling Mechanisms Underlying Epileptogenesis Sci. Signal., October 10, 2006; 2006(356): re12 - re12. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Blair, L. S. Deshpande, S. Sombati, K. W. Falenski, B. R. Martin, and R. J. DeLorenzo Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1072 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hu, K. Lindenberger, G. Hu, H. Wang, R. J. Lukas, and J. Wu Iptakalim as a Human Nicotinic Acetylcholine Receptor Antagonist J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 914 - 925. [Abstract] [Full Text] [PDF] |
||||